Erika Richtig
Publications by Year
Research Areas
Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, CAR-T cell therapy research
Most-Cited Works
- → Diagnostic Applicability of In Vivo Confocal Laser Scanning Microscopy in Melanocytic Skin Tumors(2005)232 cited
- → Problems and challenges of predatory journals(2018)214 cited
- → Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial(2022)209 cited
- → Sensitivity and specificity of confocal laser‐scanning microscopy for in vivo diagnosis of malignant skin tumors(2006)180 cited
- → Age-related prevalence of dermoscopy patterns in acquired melanocytic naevi(2005)141 cited
- → Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i(2020)123 cited
- → Body mass index may predict the response to ipilimumab in metastatic melanoma: An observational multi-centre study(2018)119 cited
- → Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial(2018)98 cited
- → Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities(2003)96 cited
- → Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma(2017)88 cited